Summary
The distribution of the acetylator phenotype of isoniazid was studied in 458 patients of different ages, and the influence of age on its apparent distribution volume, clearance and half-life was investigated in slow and rapid acetylators. The doses of isoniazid for the patients were determined according to the inactivation index method, as described by Vivien. Apparent distribution volume showed no difference between slow and rapid acetylators but it did decrease significantly with age. Clearance and half-life varied significantly in slow acetylators, and these variations led to a decrease in the necessary dose of isoniazid.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Weber WW, Hein DW (1979) Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 4: 401–422
Vivien JN, Thibier R, Lepeuple A (1973) La pharmacocinétique de l'isoniazide dans la race blanche. Rev Fr Mal Respir 5-6: 753–772
Price Evans DA, Manley KA, Mc Kusick VA (1960) Genetic control of isoniazid metabolism in man. Br Med J 42: 485–491
Farah F, Taylor W, Rawlins MD, James O (1977) Hepatic drug acetylation and oxydation: effects of aging in man. Br Med J 2: 155–156
Advenier C, Saint-Aubin A, Gobert C, Houin G, Algembres E, Tillement JP (1980) Pharmacokinetics of isoniazid in the elderly. Br J Clin Pharmacol 10: 167–169
Iselius L, Evans DAP (1983) Formal genetics of isoniazid metabolism in man. Clin Pharmacokinet 8: 541–544
Gachályi B, Vas Á, Hajós P, Káldor A (1984) Acetylator phenotypes: Effect of age. Eur J Clin Pharmacol 26: 43–45
Advenier C, Saint-Aubin A, Scheinmann P, Paupe J (1981) Pharmacocinétique de l'isoniazide chez l'enfant. Rev Fr Mal Respir 9: 365–374
Olson WA, Pruitt AW, Dayton PG (1981) Plasma concentrations of isoniazid in children with tuberculous infections 67: 876–878
Houin G, Tillement JP (1980) Conséquences thérapeutiques de l'indice d'inactivation de l'isoniazide au cours du traitement antituberculeux. Thérapie 35: 597–605
Public Health Service, US Department of Health, Education and Welfare (1974) Isoniazid-associated hepatitis: Summary of the report of the tuberculosis committee and special consultants to the director. Center for Disease Control Morbid Moral 23: 97–98
Thénault P, Saltiel JC, Houin G, Vivien JN, Tillement JP, Chrétien J (1976) Comparaison de deux méthodes de dosage de l'INH sérique. Etude de 50 patients. Thérapie 31: 747–754
Scott EM, Wright RJC (1967) Fluorimetric determination of isonicotinic acid hydrazide in serum. J Lab Clin Invest 70: 355–360
Ellard GA, Gammon PT (1976) Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 4: 83–113
Jenne JW (1960) Studies of human patterns of isoniazid metabolism using an intravenous fall-off technique with a chemical method. Am Rev Res Dis 81: 1–8
Cheminat JC, Paire M, Lavarenne J, Ducarrouge C, Molina CL (1983) Surveillance de l'INHémie plasmatique chez plus de 200 adultes. Rev Fr Mal Respir 11: 167
Delormas P, Bonneau V (1978) Considérations pratiques pour l'utilisation de l'isoniazide. Nouv Press Méd 40: 3666
Jenne SW, Mac Donald FM, Mendoza E (1961) A study of the renal clearances, metabolic activation rates and serum fall-off interaction of isoniazid and para-aminosalicylic acid in man. Am Rev Res Dis 84: 371–378
Crooks J, O'Malley K, Stevenson IH (1976) Pharmacokinetics in the elderly. Clin Pharmacokinet 1: 280–296
Bowersox DW, Winterbauer RH, Stewart GL, Orme B, Barron E (1973) Isoniazid dosage in patients with renal failure. N Engl J Med 289: 84–87
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kergueris, M.F., Bourin, M. & Larousse, C. Pharmacokinetics of isoniazid: Influence of age. Eur J Clin Pharmacol 30, 335–340 (1986). https://doi.org/10.1007/BF00541539
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00541539